Natera
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Natera 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About NTRA
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
CEOStephen Leonard Chapman
CEOStephen Leonard Chapman
Employees4,434
Employees4,434
HeadquartersAustin, Texas
HeadquartersAustin, Texas
Founded2003
Founded2003
Employees4,434
Employees4,434
NTRA Key Statistics
Market cap23.55B
Market cap23.55B
Price-Earnings ratio-88.64
Price-Earnings ratio-88.64
Dividend yield—
Dividend yield—
Average volume1.24M
Average volume1.24M
High today$173.62
High today$173.62
Low today$167.33
Low today$167.33
Open price$170.46
Open price$170.46
Volume1.05M
Volume1.05M
52 Week high$183.00
52 Week high$183.00
52 Week low$117.27
52 Week low$117.27
NTRA News
Simply Wall St 2d
Natera's Enrollment Surge in EXPAND Trial Could Be a Game Changer for NateraNatera recently announced a major milestone in its EXPAND clinical trial, surpassing 1,600 enrolled patients for the Fetal Focus single gene noninvasive prenata...
Simply Wall St 4d
Natera: Exploring Valuation as Share Price Pulls Back Despite Strong GrowthNatera (NTRA) shares have pulled back by roughly 5% over the past month, even after reporting double-digit annual revenue growth and significant improvements in...
Simply Wall St 5d
Natera: Assessing Valuation Potential as Shares Enter a Quiet PhaseNatera (NTRA) shares have seen modest movement during a relatively quiet period. This offers investors a chance to reassess the company’s fundamentals and consi...
Analyst ratings
90%
of 21 ratingsBuy
90.5%
Hold
4.8%
Sell
4.8%
More NTRA News
TipRanks 7d
Natera enrolls over 1,600 patients in EXPAND trialNatera (NTRA) announced a milestone in the EXPAND trial with the enrollment of over 1,600 patients. Elevate Your Investing Strategy: Take advantage of TipRank...
People also own
Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.